IL17A and breast carcinoma: Despite this and other unknowns, targeting TIM-3, IL-1β receptors, IL-17+ γδ T cells, IL-17 and their downstream immunological effectors (perhaps including CX3CR1+ TAMs) (Paul et al, 2024) represent promising strategies to limit metastatic dissemination and resistance to therapy in multiple breast cancer subtypes.